Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

329
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
329
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

349
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
349
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

313
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
313
Autoimmune Disorders01:29

Autoimmune Disorders

1.2K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
1.2K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

317
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
317
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A case of normocalcaemic primary hyperparathyroidism misdiagnosed as ankylosing spondylitis.

Scandinavian journal of rheumatology·2025
Same author

An observational study of ultrasound semiquantitative scoring for predicting the risk of gout flare.

Zeitschrift fur Rheumatologie·2024
Same author

The Role of Ultrasound Semi-Quantitative Scoring in the Diagnosis and Assessment of Gout and Hyperuricemia.

Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine·2023
Same author

Ulcerative rash in a patient with anti-MDA5 antibody-associated clinically amyopathic dermatomyositis.

Clinical rheumatology·2023
Same author

Severe deformity in long-term Kaschin-Beck disease.

Rheumatology (Oxford, England)·2021
Same author

Progress in interleukin-2 therapy for rheumatic immune diseases by regulating the immune balance of T cells.

Scandinavian journal of immunology·2019

Related Experiment Video

Updated: Dec 3, 2025

Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research
07:25

Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research

Published on: October 13, 2023

4.3K

Biologic therapy in Sjögren's syndrome.

Qin Shao1

  • 1Department of Rheumatology, Chongqing City Hospital of Traditional Chinese Medicine, No.6, Pan Xi Qi Zhi Road, Jiang Bei District, Chongqing, 400021, China. qinshao2011@126.com.

Clinical Rheumatology
|October 27, 2020
PubMed
Summary
This summary is machine-generated.

Sjögren's syndrome (SS) is an autoimmune disease causing dry eyes and mouth. This review analyzes biological treatments targeting molecular pathways to improve therapeutic strategies for SS patients.

Keywords:
Biologic therapyClinical trialSjögren’s syndrome

More Related Videos

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

653
Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients
05:26

Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients

Published on: March 1, 2024

1.6K

Related Experiment Videos

Last Updated: Dec 3, 2025

Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research
07:25

Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research

Published on: October 13, 2023

4.3K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

653
Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients
05:26

Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients

Published on: March 1, 2024

1.6K

Area of Science:

  • Immunology
  • Rheumatology
  • Autoimmune Diseases

Background:

  • Sjögren's syndrome (SS) is a chronic autoimmune disorder affecting exocrine glands, leading to dry eyes and mouth.
  • Systemic complications can arise from extraglandular organ involvement.
  • Current treatments focus on symptom management due to unclear pathogenesis and lack of effective therapies.

Purpose of the Study:

  • To review and analyze the efficacy of biological agents in treating Sjögren's syndrome.
  • To identify the molecular targets of these biological therapies.
  • To explore improvements in treatment strategies for SS.

Main Methods:

  • Systematic review of existing evidence on biological treatments for SS.
  • Analysis of data on treatment efficacy and targeted pathways.
  • Evaluation of potential improvements in therapeutic approaches.

Main Results:

  • Biological agents show promise in treating Sjögren's syndrome by targeting specific molecular pathways.
  • Evidence suggests varying efficacy depending on the agent and targeted mechanism.
  • Further analysis can optimize the use of biological therapies.

Conclusions:

  • Biological therapies represent a developing treatment avenue for Sjögren's syndrome.
  • Understanding molecular targets is crucial for enhancing treatment efficacy.
  • Improved strategies are needed to maximize the benefits of biological treatments for SS.